These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10342986)

  • 1. Lessons learned from good manufacturing practice noncompliance.
    Peskoe MP
    Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986
    [No Abstract]   [Full Text] [Related]  

  • 2. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 3. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control and good manufacturing practices: safety and efficacy of commercial herbals.
    Awang DV
    Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036
    [No Abstract]   [Full Text] [Related]  

  • 5. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 6. A millstone in the uphill battle for credibility.
    Czap A
    Altern Med Rev; 2001 Feb; 6(1):3. PubMed ID: 11207452
    [No Abstract]   [Full Text] [Related]  

  • 7. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 8. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 9. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx, radiology, and the Food and Drug Administration.
    Pentecost MJ
    J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
    [No Abstract]   [Full Text] [Related]  

  • 11. Contaminated dietary supplements.
    Carvajal R
    N Engl J Med; 2010 Jan; 362(3):274; author reply 274. PubMed ID: 20089984
    [No Abstract]   [Full Text] [Related]  

  • 12. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 14. [State surveillance and control of food quality and safety in USA].
    Berman VA
    Vopr Pitan; 2003; 72(2):22-7. PubMed ID: 12924205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 16. GMP criteria for retest and failure analysis. Handling out-of-specification results in the pharmaceutical quality control laboratory.
    Klein AE; Rocci ML
    Qual Assur; 1995 Dec; 4(4):247-51. PubMed ID: 8890350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulation of biotechnologies: four recommendations.
    Fox D
    Hastings Cent Rep; 2008; 38(2):1 p following 56. PubMed ID: 18457229
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical industry wins "round one" in protections against product liability claims.
    Gatty B
    Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868
    [No Abstract]   [Full Text] [Related]  

  • 20. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.